|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Progenra, Inc.'s Novel USP7 Inhibitors are Shown to Exert Multiple Anti-Tumor Effects
10/8/2012 10:09:45 AM
MALVERN, PA.--(BUSINESS WIRE)--Researchers at Progenra, Inc. announce the advanced online publication of the article “Selective Dual Inhibitors of the Cancer-related Deubiquitylating Proteases USP7 and USP47” (Weinstock, J. et al, ACS Medicinal Chemistry Letters). The new article presents evidence of a therapeutic benefit resulting from dual inhibition of USP7 and a related enzyme, USP47. Additionally, data presented in this publication amplify the recent work published by Progenra and the Dana Farber Cancer Institute, showing that the parent compound of this series blocks USP7 activity in cells and exhibits antitumor activity in bortezomib-resistant myeloma models (Chauhan et al., Cancer Cell 22 (2012), 345-358).
|
|
|
|
|
|
|
|
|
|
|